Pacemaker ve ICD Endikasyonu Belirlemede Kullanılan Testler-Kardiyak Görüntüleme (EKO ve MRG)

Elmqvist R, Senning R. An implantable pacemaker for heart: In proceedings of seventh intl conf. of electrical engineers. Hiffe, London; 1959.

Mirowski M, Mower MM, Langer A, Heilman MS, a chronically implante system for automatic defibrillation in active conscious dogs: experimental model for treatment of sudden death from ventricular fibrillation. Circulation. 1978;58(1): 90-94. doi: 10.1161/01.cir.58.1.90.

Halliday BP, Gulati A, Ali A, association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135(22): 2106-2115. doi: 10.1161/CIRCULATIONAHA.116.026910.

Ferreira VM, Schulz-Menger J, Holmvang G, cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24): 3158-3176. doi: 10.1016/j.jacc.2018.09.072.

van der Bijl P, Delgado V, Bax JJ, imaging for sudden cardiac death risk stratification: current perspective and future directions. Prog Cardiovasc Dis. 2019;62(3): 205-211. doi: 10.1016/j.pcad.2019.04.005.

Winkel BG, Holst AG, Theilade J, nationwide study of sudden cardiac death in persons aged 1–35 years. Eur Heart J. 2011;32(8): 983-990. doi: 10.1093/eurheartj/ehq428.

Waldmann V, Karam N, Bougouin W, burden of coronary artery disease as a cause of sudden cardiac arrest in the young. J Am Coll Cardiol 2019;73(16): 2118-2120. doi: 10.1016/j.jacc.2019.01.064.

Risgaard B, Winkel BG, Jabbari R, burden of sudden cardiac death in persons aged 1 to 49 years: nationwide study in Denmark. Circ Arrhythm Electrophysiol. 2014;7(2): 205-211. doi: 10.1161/CIRCEP.113.001421.

Moss AJ, Hall WJ, Cannom DS, improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335(26): 1933-1940. doi: 10.1056/NEJM199612263352601.

Buxton AE, Lee KL, Fisher JD, a randomized study of the prevention of sudden death in patients with coronary artery dis- ease. multicenter unsustained tachycardia Trial Investigators. N Engl J Med. 1999; 341(25): 1882-1890. doi: 10.1056/NEJM199912163412503.

Haugaa KH, Grenne BL, Eek CH, strain echocardiography improves risk prediction of ventricular arrhythmias after myocardial infarction. JACC Cardiovasc Imaging. 2013;6(8): 841-850. doi: 10.1016/j.jcmg.2013.03.005.

Biering-Sørensen T, Knappe D, Pouleur A-C, regional longitudinal deformation improves prediction of ventricular tachyarrhythmias in patients with heart failure with reduced ejection fraction: a MADIT-CRT substudy (multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy). Circ Cardiovasc Imaging. 2017;10(1): e005096. doi: 10.1161/CIRCIMAGING.116.005096.

Moss AJ, Zareba W, Hall WJ, prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12): 877-883. doi: 10.1056/NEJMoa013474.

Ersboll M, Valeur N, Andersen MJ, early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. JACC Cardiovasc Imaging. 2013;6(8):851–860. doi: 10.1016/j.jcmg.2013.05.009.

Kim RJ, Fieno DS, Parrish TB, relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19): 1992-2002. doi: 10.1161/01.cir.100.19.1992.

Zhang L, Athavale P, Pop M, multicontrast reconstruction using compressed sensing with low rank and spatially varying edge-preserving constraints for high-resolution MR characterization of myocardial infarction. Magn Reson Med. 2017;78(2):598-610. doi: 10.1002/mrm.26402.

Izquierdo M, Ruiz-Granell R, Bonanad C, value of early cardiovascular magnetic resonance for the prediction of adverse arrhythmic cardiac events after a first noncomplicated ST-segment-ele-vation myocardial infarction. Circ Cardiovasc Imaging. 2013;6(5):755-761. doi: 10.1161/CIRCIMAGING.113.000702.

Klem I, Weinsaft JW, Bahnson TD, assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol. 2012;60(5): 408-420. doi: 10.1016/j.jacc.2012.02.070.

Raymond JM, Sacher F, Winslow R, catheter ablation for scar-related ventricular tachycardias. Curr Probl Cardiol. 2009;34(5): 225-270. doi: 10.1016/j.cpcardiol.2009.01.002.

Yan AT, Shayne AJ, Brown KA, characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114(1): 32-39. doi: 10.1161/CIRCULATIONAHA.106.613414.

Roes SD, Borleffs CJ, van der Geest RJ, infarct tissue heterogeneity assessed with contrast- enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ Cardiovasc Imaging. 2009;2(3):183-190. doi: 10.1161/CIRCIMAGING.108.826529.

Wu KC, Gerstenblith G, Guallar E, combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging. 2012;5(2):178-186. doi: 10.1161/CIRCIMAGING.111.968024.

Zabel M, Willems R, Lubinski A, clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J. 2020;41(36): 3437-3447. doi: 10.1093/eurheartj/ehaa226.

Kadish A, Dyer A, Daubert JP, prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21): 2151-2158. doi: 10.1056/NEJMoa033088.

Kober L, Thune JJ, Nielsen JC, defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13): 1221-1230. doi: 10.1056/NEJMoa1608029.

Wu KC, Weiss RG, Thiemann DR, late gadolinium enhancement bycardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51(25): 2414-2421. doi: 10.1016/j.jacc.2008.03.018.

Halliday B, Gulati A, Ali A, association between mid-wall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolicdysfunction. Circulation. 2017;135(22): 2106-2115. doi: 10.1161/CIRCULATIONAHA.116.026910.

Bogun FM, Desjardins B, Good E, delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. 2009;53(13): 1138-1145. doi: 10.1016/j.jacc.2008.11.052.

Miron A, Lafreniere-Roula M, Fan CS, a validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation. 2020;142(3): 217-29. doi: 10.1161/CIRCULATIONAHA.120.047235.

Norrish G, Ding T, Field E, development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM risk-kids). JAMA Cardiol. 2019;4(9): 918-927. doi: 10.1001/jamacardio.2019.2861.

Wells S, Rowin EJ, Bhatt V, association between race and clinical profile of patients referred for hypertrophic cardiomyopathy. Circulation. 2018;137(18): 1973–1975. doi: 10.1161/CIRCULATIONAHA.117.032838.

Olivotto I, Maron MS, Adabag AS, gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3): 480-487. doi: 10.1016/j.jacc.2005.04.043.

Adabag AS, Kuskowski MA, Maron BJ, determinants for clinical diagnosis of hypertrophic cardiomyopathy. Am J Cardiol. 2006;98(11): 1507-1511. doi: 10.1016/j.amjcard.2006.07.029.

Douglas PS, Garcia MJ, Haines DE, ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2011;57(9): 1126-66. doi: 10.1016/j.jacc.2010.11.002.

Kumar S, Van Ness G, Bender A, standardized goal-directed Valsalva maneuver for assessment of inducible left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2018;31(7): 791-798. doi: 10.1016/j.echo.2018.01.022.

Joshi S, Patel UK, Yao S-S, standing and exercise doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity. J Am Soc Echocardiogr. 2011;24(1): 75-82. doi: 10.1016/j.echo.2010.10.006.

Grigg LE, Wigle ED, Williams WG, transesophageal doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol. 1992;20(1): 42-52. doi: 10.1016/0735-1097(92)90135-a.

Spirito P, Bellone P, Harris KM, magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24): 1778-1785. doi: 10.1056/NEJM200006153422403.

Maron MS, Maron BJ, Harrigan C, hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(3) :220-228. doi: 10.1016/j.jacc.2009.05.006.

Maron MS, Rowin EJ, Maron BJ, how to image hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2017;10(7): e0053272. doi: 10.1161/CIRCIMAGING.116.005372.

Rickers C, Wilke NM, Jerosch-Herold M, utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112(6): 855-861. doi: 10.1161/CIRCULATIONAHA.104.507723.

Maron MS, clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14(1):13. doi: 10.1186/1532-429X-14-13.

Maron BJ, Maron MS, LGE means better selection of HCM patients for primary prevention implantable defibrillators. JACC Cardiovasc Imaging. 2016;9(12): 1403-1406. doi: 10.1016/j.jcmg.2016.01.032.

Corrado D, Link MS, Calkins H, arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376(1): 1489-1490. doi: 10.1056/NEJMra1509267.

Bhonsale A, Groeneweg JA, James CA, impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J 2015;36(14): 847-855. doi: 10.1093/eurheartj/ehu509.

Marcus FI, McKenna WJ, Sherrill D, diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Eur Heart J 2010;31(7): 806-814. doi: 10.1093/eurheartj/ehq025.

Canpolat U, Kabakçi G, Aytemir K, fragmented QRS complex predicts the arrhythmic events in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Cardiovasc Electrophysiol. 2013;24(11): 1260-1266. doi: 10.1111/jce.12202.

te Riele ASJM, Bhonsale A, James CA, incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62(19): 1761-1769. doi: 10.1016/j.jacc.2012.11.087.

Aquaro GD, Barison A, Todiere G, usefulness of combined functional assessment by cardiac magnetic resonance and tissue characterization versus task force criteria for diagnosis of arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2016;118(11): 1730-1736. doi: 10.1016/j.amjcard.2016.08.056.

Bhonsale A, James CA, Tichnell C, incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011;58(14): 1485-1496. doi: 10.1016/j.jacc.2011.06.043.

Grigoratos C, Barison A, Ivanov A, meta-analysis of the prognostic role of late gadolinium enhancement and global systolic impairment in left ventricular noncompaction. JACC Cardiovasc Imaging. 2019;12(11 Pt 1): 2141-2151. doi: 10.1016/j.jcmg.2018.12.029.

Murtagh G, Laffin LJ, Beshai JF, prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2016;9(1):e003738. doi: 10.1161/CIRCIMAGING.115.003738.

Elmqvist R, Senning R. An implantable pacemaker for heart: In proceedings of seventh intl conf. of electrical engineers. Hiffe, London; 1959.

Mirowski M, Mower MM, Langer A, Heilman MS, a chronically implante system for automatic defibrillation in active conscious dogs: experimental model for treatment of sudden death from ventricular fibrillation. Circulation. 1978;58(1): 90-94. doi: 10.1161/01.cir.58.1.90.

Halliday BP, Gulati A, Ali A, association between midwall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolic dysfunction. Circulation. 2017;135(22): 2106-2115. doi: 10.1161/CIRCULATIONAHA.116.026910.

Ferreira VM, Schulz-Menger J, Holmvang G, cardiovascular magnetic resonance in nonischemic myocardial inflammation: expert recommendations. J Am Coll Cardiol. 2018;72(24): 3158-3176. doi: 10.1016/j.jacc.2018.09.072.

van der Bijl P, Delgado V, Bax JJ, imaging for sudden cardiac death risk stratification: current perspective and future directions. Prog Cardiovasc Dis. 2019;62(3): 205-211. doi: 10.1016/j.pcad.2019.04.005.

Winkel BG, Holst AG, Theilade J, nationwide study of sudden cardiac death in persons aged 1–35 years. Eur Heart J. 2011;32(8): 983-990. doi: 10.1093/eurheartj/ehq428.

Waldmann V, Karam N, Bougouin W, burden of coronary artery disease as a cause of sudden cardiac arrest in the young. J Am Coll Cardiol 2019;73(16): 2118-2120. doi: 10.1016/j.jacc.2019.01.064.

Risgaard B, Winkel BG, Jabbari R, burden of sudden cardiac death in persons aged 1 to 49 years: nationwide study in Denmark. Circ Arrhythm Electrophysiol. 2014;7(2): 205-211. doi: 10.1161/CIRCEP.113.001421.

Moss AJ, Hall WJ, Cannom DS, improved survival with an implanted defibrillator in patients with coronary disease at high risk for ventricular arrhythmia. N Engl J Med. 1996;335(26): 1933-1940. doi: 10.1056/NEJM199612263352601.

Buxton AE, Lee KL, Fisher JD, a randomized study of the prevention of sudden death in patients with coronary artery dis- ease. multicenter unsustained tachycardia Trial Investigators. N Engl J Med. 1999; 341(25): 1882-1890. doi: 10.1056/NEJM199912163412503.

Haugaa KH, Grenne BL, Eek CH, strain echocardiography improves risk prediction of ventricular arrhythmias after myocardial infarction. JACC Cardiovasc Imaging. 2013;6(8): 841-850. doi: 10.1016/j.jcmg.2013.03.005.

Biering-Sørensen T, Knappe D, Pouleur A-C, regional longitudinal deformation improves prediction of ventricular tachyarrhythmias in patients with heart failure with reduced ejection fraction: a MADIT-CRT substudy (multicenter automatic defibrillator implantation trial-cardiac resynchronization therapy). Circ Cardiovasc Imaging. 2017;10(1): e005096. doi: 10.1161/CIRCIMAGING.116.005096.

Moss AJ, Zareba W, Hall WJ, prophylactic implantation of a defibrillator in patients with myocardial infarction and reduced ejection fraction. N Engl J Med. 2002;346(12): 877-883. doi: 10.1056/NEJMoa013474.

Ersboll M, Valeur N, Andersen MJ, early echocardiographic deformation analysis for the prediction of sudden cardiac death and life-threatening arrhythmias after myocardial infarction. JACC Cardiovasc Imaging. 2013;6(8):851–860. doi: 10.1016/j.jcmg.2013.05.009.

Kim RJ, Fieno DS, Parrish TB, relationship of MRI delayed contrast enhancement to irreversible injury, infarct age, and contractile function. Circulation. 1999;100(19): 1992-2002. doi: 10.1161/01.cir.100.19.1992.

Zhang L, Athavale P, Pop M, multicontrast reconstruction using compressed sensing with low rank and spatially varying edge-preserving constraints for high-resolution MR characterization of myocardial infarction. Magn Reson Med. 2017;78(2):598-610. doi: 10.1002/mrm.26402.

Izquierdo M, Ruiz-Granell R, Bonanad C, value of early cardiovascular magnetic resonance for the prediction of adverse arrhythmic cardiac events after a first noncomplicated ST-segment-ele-vation myocardial infarction. Circ Cardiovasc Imaging. 2013;6(5):755-761. doi: 10.1161/CIRCIMAGING.113.000702.

Klem I, Weinsaft JW, Bahnson TD, assessment of myocardial scarring improves risk stratification in patients evaluated for cardiac defibrillator implantation. J Am Coll Cardiol. 2012;60(5): 408-420. doi: 10.1016/j.jacc.2012.02.070.

Raymond JM, Sacher F, Winslow R, catheter ablation for scar-related ventricular tachycardias. Curr Probl Cardiol. 2009;34(5): 225-270. doi: 10.1016/j.cpcardiol.2009.01.002.

Yan AT, Shayne AJ, Brown KA, characterization of the peri-infarct zone by contrast-enhanced cardiac magnetic resonance imaging is a powerful predictor of post-myocardial infarction mortality. Circulation. 2006;114(1): 32-39. doi: 10.1161/CIRCULATIONAHA.106.613414.

Roes SD, Borleffs CJ, van der Geest RJ, infarct tissue heterogeneity assessed with contrast- enhanced MRI predicts spontaneous ventricular arrhythmia in patients with ischemic cardiomyopathy and implantable cardioverter-defibrillator. Circ Cardiovasc Imaging. 2009;2(3):183-190. doi: 10.1161/CIRCIMAGING.108.826529.

Wu KC, Gerstenblith G, Guallar E, combined cardiac magnetic resonance imaging and C-reactive protein levels identify a cohort at low risk for defibrillator firings and death. Circ Cardiovasc Imaging. 2012;5(2):178-186. doi: 10.1161/CIRCIMAGING.111.968024.

Zabel M, Willems R, Lubinski A, clinical effectiveness of primary prevention implantable cardioverter-defibrillators: results of the EU-CERT-ICD controlled multicentre cohort study. Eur Heart J. 2020;41(36): 3437-3447. doi: 10.1093/eurheartj/ehaa226.

Kadish A, Dyer A, Daubert JP, prophylactic defibrillator implantation in patients with nonischemic dilated cardiomyopathy. N Engl J Med. 2004;350(21): 2151-2158. doi: 10.1056/NEJMoa033088.

Kober L, Thune JJ, Nielsen JC, defibrillator implantation in patients with nonischemic systolic heart failure. N Engl J Med. 2016;375(13): 1221-1230. doi: 10.1056/NEJMoa1608029.

Wu KC, Weiss RG, Thiemann DR, late gadolinium enhancement bycardiovascular magnetic resonance heralds an adverse prognosis in nonischemic cardiomyopathy. J Am Coll Cardiol. 2008;51(25): 2414-2421. doi: 10.1016/j.jacc.2008.03.018.

Halliday B, Gulati A, Ali A, association between mid-wall late gadolinium enhancement and sudden cardiac death in patients with dilated cardiomyopathy and mild and moderate left ventricular systolicdysfunction. Circulation. 2017;135(22): 2106-2115. doi: 10.1161/CIRCULATIONAHA.116.026910.

Bogun FM, Desjardins B, Good E, delayed-enhanced magnetic resonance imaging in nonischemic cardiomyopathy: utility for identifying the ventricular arrhythmia substrate. J Am Coll Cardiol. 2009;53(13): 1138-1145. doi: 10.1016/j.jacc.2008.11.052.

Miron A, Lafreniere-Roula M, Fan CS, a validated model for sudden cardiac death risk prediction in pediatric hypertrophic cardiomyopathy. Circulation. 2020;142(3): 217-29. doi: 10.1161/CIRCULATIONAHA.120.047235.

Norrish G, Ding T, Field E, development of a novel risk prediction model for sudden cardiac death in childhood hypertrophic cardiomyopathy (HCM risk-kids). JAMA Cardiol. 2019;4(9): 918-927. doi: 10.1001/jamacardio.2019.2861.

Wells S, Rowin EJ, Bhatt V, association between race and clinical profile of patients referred for hypertrophic cardiomyopathy. Circulation. 2018;137(18): 1973–1975. doi: 10.1161/CIRCULATIONAHA.117.032838.

Olivotto I, Maron MS, Adabag AS, gender-related differences in the clinical presentation and outcome of hypertrophic cardiomyopathy. J Am Coll Cardiol. 2005;46(3): 480-487. doi: 10.1016/j.jacc.2005.04.043.

Adabag AS, Kuskowski MA, Maron BJ, determinants for clinical diagnosis of hypertrophic cardiomyopathy. Am J Cardiol. 2006;98(11): 1507-1511. doi: 10.1016/j.amjcard.2006.07.029.

Douglas PS, Garcia MJ, Haines DE, ACCF/ASE/AHA/ASNC/HFSA/HRS/SCAI/SCCM/SCCT/SCMR 2011 appropriate use criteria for echocardiography. A report of the American College of Cardiology Foundation Appropriate Use Criteria Task Force, American Society of Echocardiography, American Heart Association, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, Society of Critical Care Medicine, Society of Cardiovascular Computed Tomography, and Society for Cardiovascular Magnetic Resonance. J Am Coll Cardiol. 2011;57(9): 1126-66. doi: 10.1016/j.jacc.2010.11.002.

Kumar S, Van Ness G, Bender A, standardized goal-directed Valsalva maneuver for assessment of inducible left ventricular outflow tract obstruction in hypertrophic cardiomyopathy. J Am Soc Echocardiogr. 2018;31(7): 791-798. doi: 10.1016/j.echo.2018.01.022.

Joshi S, Patel UK, Yao S-S, standing and exercise doppler echocardiography in obstructive hypertrophic cardiomyopathy: the range of gradients with upright activity. J Am Soc Echocardiogr. 2011;24(1): 75-82. doi: 10.1016/j.echo.2010.10.006.

Grigg LE, Wigle ED, Williams WG, transesophageal doppler echocardiography in obstructive hypertrophic cardiomyopathy: clarification of pathophysiology and importance in intraoperative decision making. J Am Coll Cardiol. 1992;20(1): 42-52. doi: 10.1016/0735-1097(92)90135-a.

Spirito P, Bellone P, Harris KM, magnitude of left ventricular hypertrophy and risk of sudden death in hypertrophic cardiomyopathy. N Engl J Med. 2000;342(24): 1778-1785. doi: 10.1056/NEJM200006153422403.

Maron MS, Maron BJ, Harrigan C, hypertrophic cardiomyopathy phenotype revisited after 50 years with cardiovascular magnetic resonance. J Am Coll Cardiol. 2009;54(3) :220-228. doi: 10.1016/j.jacc.2009.05.006.

Maron MS, Rowin EJ, Maron BJ, how to image hypertrophic cardiomyopathy. Circ Cardiovasc Imaging. 2017;10(7): e0053272. doi: 10.1161/CIRCIMAGING.116.005372.

Rickers C, Wilke NM, Jerosch-Herold M, utility of cardiac magnetic resonance imaging in the diagnosis of hypertrophic cardiomyopathy. Circulation. 2005;112(6): 855-861. doi: 10.1161/CIRCULATIONAHA.104.507723.

Maron MS, clinical utility of cardiovascular magnetic resonance in hypertrophic cardiomyopathy. J Cardiovasc Magn Reson. 2012;14(1):13. doi: 10.1186/1532-429X-14-13.

Maron BJ, Maron MS, LGE means better selection of HCM patients for primary prevention implantable defibrillators. JACC Cardiovasc Imaging. 2016;9(12): 1403-1406. doi: 10.1016/j.jcmg.2016.01.032.

Corrado D, Link MS, Calkins H, arrhythmogenic right ventricular cardiomyopathy. N Engl J Med. 2017;376(1): 1489-1490. doi: 10.1056/NEJMra1509267.

Bhonsale A, Groeneweg JA, James CA, impact of genotype on clinical course in arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated mutation carriers. Eur Heart J 2015;36(14): 847-855. doi: 10.1093/eurheartj/ehu509.

Marcus FI, McKenna WJ, Sherrill D, diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. Eur Heart J 2010;31(7): 806-814. doi: 10.1093/eurheartj/ehq025.

Canpolat U, Kabakçi G, Aytemir K, fragmented QRS complex predicts the arrhythmic events in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. J Cardiovasc Electrophysiol. 2013;24(11): 1260-1266. doi: 10.1111/jce.12202.

te Riele ASJM, Bhonsale A, James CA, incremental value of cardiac magnetic resonance imaging in arrhythmic risk stratification of arrhythmogenic right ventricular dysplasia/cardiomyopathy-associated desmosomal mutation carriers. J Am Coll Cardiol. 2013;62(19): 1761-1769. doi: 10.1016/j.jacc.2012.11.087.

Aquaro GD, Barison A, Todiere G, usefulness of combined functional assessment by cardiac magnetic resonance and tissue characterization versus task force criteria for diagnosis of arrhythmogenic right ventricular cardiomyopathy. Am J Cardiol. 2016;118(11): 1730-1736. doi: 10.1016/j.amjcard.2016.08.056.

Bhonsale A, James CA, Tichnell C, incidence and predictors of implantable cardioverter-defibrillator therapy in patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy undergoing implantable cardioverter-defibrillator implantation for primary prevention. J Am Coll Cardiol. 2011;58(14): 1485-1496. doi: 10.1016/j.jacc.2011.06.043.

Grigoratos C, Barison A, Ivanov A, meta-analysis of the prognostic role of late gadolinium enhancement and global systolic impairment in left ventricular noncompaction. JACC Cardiovasc Imaging. 2019;12(11 Pt 1): 2141-2151. doi: 10.1016/j.jcmg.2018.12.029.

Murtagh G, Laffin LJ, Beshai JF, prognosis of myocardial damage in sarcoidosis patients with preserved left ventricular ejection fraction: risk stratification using cardiovascular magnetic resonance. Circ Cardiovasc Imaging. 2016;9(1):e003738. doi: 10.1161/CIRCIMAGING.115.003738.